Current Knowledge in Thyroid Cancer - From Bench to Bedside / / edited by Daniela Gabriele Grimm.
In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel : : MDPI,, 2017. ©2017 |
Year of Publication: | 2017 |
Edition: | First Edition. |
Language: | English |
Physical Description: | 1 online resource (viii, 212 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993561969104498 |
---|---|
ctrlnum |
(CKB)5400000000000043 (NjHacI)995400000000000043 (EXLCZ)995400000000000043 |
collection |
bib_alma |
record_format |
marc |
spelling |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / edited by Daniela Gabriele Grimm. First Edition. Basel : MDPI, 2017. ©2017 1 online resource (viii, 212 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (directory.doabooks.org, viewed February 23, 2023). In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer. Includes bibliographical references and index. Thyroid hormones. Grimm, Daniela Gabriele, editor. |
language |
English |
format |
eBook |
author2 |
Grimm, Daniela Gabriele, |
author_facet |
Grimm, Daniela Gabriele, |
author2_variant |
d g g dg dgg |
author2_role |
TeilnehmendeR |
title |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / |
spellingShingle |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / |
title_full |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / edited by Daniela Gabriele Grimm. |
title_fullStr |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / edited by Daniela Gabriele Grimm. |
title_full_unstemmed |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / edited by Daniela Gabriele Grimm. |
title_auth |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / |
title_new |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / |
title_sort |
current knowledge in thyroid cancer - from bench to bedside / |
publisher |
MDPI, |
publishDate |
2017 |
physical |
1 online resource (viii, 212 pages) |
edition |
First Edition. |
isbn |
3-03842-477-3 |
callnumber-first |
Q - Science |
callnumber-subject |
QP - Physiology |
callnumber-label |
QP572 |
callnumber-sort |
QP 3572 T5 C877 42017 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
612 - Human physiology |
dewey-full |
612.44 |
dewey-sort |
3612.44 |
dewey-raw |
612.44 |
dewey-search |
612.44 |
work_keys_str_mv |
AT grimmdanielagabriele currentknowledgeinthyroidcancerfrombenchtobedside |
status_str |
n |
ids_txt_mv |
(CKB)5400000000000043 (NjHacI)995400000000000043 (EXLCZ)995400000000000043 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Current Knowledge in Thyroid Cancer - From Bench to Bedside / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1764993889768308736 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02466nam a2200325 i 4500</leader><controlfield tag="001">993561969104498</controlfield><controlfield tag="005">20230224152607.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230224s2017 sz ob 001 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03842-477-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/books978-3-03842-477-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000000043</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000000043</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000000043</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QP572.T5</subfield><subfield code="b">.C877 2017</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">612.44</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Current Knowledge in Thyroid Cancer - From Bench to Bedside /</subfield><subfield code="c">edited by Daniela Gabriele Grimm.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First Edition.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI,</subfield><subfield code="c">2017.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (viii, 212 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (directory.doabooks.org, viewed February 23, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Thyroid hormones.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grimm, Daniela Gabriele,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 00:37:37 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-10-31 22:37:04 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337465690004498&Force_direct=true</subfield><subfield code="Z">5337465690004498</subfield><subfield code="8">5337465690004498</subfield></datafield></record></collection> |